Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Cost of Revenue (2019 - 2024)

Benitec Biopharma's Cost of Revenue history spans 6 years, with the latest figure at $3000.0 for Q1 2024.

  • For Q1 2024, Cost of Revenue changed N/A year-over-year to $3000.0; the TTM value through Dec 2024 reached $3000.0, down 97.2%, while the annual FY2024 figure was $108000.0, N/A changed from the prior year.
  • Cost of Revenue for Q1 2024 was $3000.0 at Benitec Biopharma, up from $1000.0 in the prior quarter.
  • Across five years, Cost of Revenue topped out at $134000.0 in Q3 2020 and bottomed at -$99000.0 in Q1 2020.
  • The 5-year median for Cost of Revenue is $5000.0 (2021), against an average of $9500.0.
  • The largest YoY upside for Cost of Revenue was 415.38% in 2020 against a maximum downside of 93.79% in 2020.
  • A 5-year view of Cost of Revenue shows it stood at $19000.0 in 2020, then tumbled by 294.74% to -$37000.0 in 2021, then soared by 124.32% to $9000.0 in 2022, then plummeted by 88.89% to $1000.0 in 2023, then skyrocketed by 200.0% to $3000.0 in 2024.
  • Per Business Quant, the three most recent readings for BNTC's Cost of Revenue are $3000.0 (Q1 2024), $1000.0 (Q4 2023), and $106000.0 (Q3 2023).